by Richard Daverman, PhD
June 1, 2012 -- Boehringer Ingelheim will invest $69 million into a veterinary vaccine medicine production facility, which will be built in Taizhou China Medical City. The new manufacturing plant follows closely on BI’s $15 million investment into an animal health R&D lab in Shanghai’s Zhangjiang Hi-Tech park, which opened in March of this year. The company wants to increase its market share in the Asia-specific animal vaccine sector. More details....
